Ubamatamab

Ubamatamab is listed on ClinicalTrials.gov as an intervention in 3 registered phase 2 trials sponsored by Regeneron Pharmaceuticals, in ovarian cancer, endometrial cancer. A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.